Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GDX012 in Relapsed or Refractory Acute Myeloid Leukemia
NCT05886491Phase 2Terminated
- Sponsor
- Takeda
- Start
- Jul 2023
- Primary completion
- Aug 2025
- Modality
- Cell Therapies
- Countries
- 2
01
Overview
A Phase 2 trial of allogeneic variable delta 1 gamma-delta T cells in acute myeloid leukemia (AML), sponsored by Takeda. Started Jul 2023; status: terminated.
02
Drugs
allogeneic variable delta 1 gamma-delta T cells
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05886491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05886491.